-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the National Medical Products Administration approved the marketing application of Novo Nordisk's Novo Nordisk® (Insulin Deglulam and Liraglutide Injection) in China, which is suitable for adults with type 2 diabetes with poor blood sugar control.
Combine other oral hypoglycemic drugs on the basis of diet and exercise to improve blood sugar control1
.
Novoyi® is the world’s first basal insulin glucagon-like peptide-1 receptor agonist (GLP-1RA) injection, composed of insulin deglubber and liraglutide2, a breakthrough combination of insulin deglu Liraglutide's two-component advantages, complementary mechanisms, multi-targeted action on multiple pathophysiological mechanisms of type 2 diabetes 3, 4, 5, once a day injection, strong control of blood glucose throughout the day, glycated hemoglobin (HbA1c) compliance rate As high as 89.
9%, the risk of hypoglycemia is reduced and the weight gain is clear6,7,8,9,10, which will bring easy-to-control blood glucose management for patients and help Chinese patients with type 2 diabetes to achieve high-quality blood glucose standards
.
At present, deglu insulin and liraglutide injection have been written into the "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)"11
The total number of diabetes patients in China reaches 129.
8 million12, and only about 15.
8% of patients have achieved blood glucose control standards13
.
Among them, type 2 diabetes accounts for the majority
references:
references:1.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
Yongze Li, et al.
BMJ.
2020 Apr 28;369:m997.
13.
Wang L, et al.
JAMA.
2017 Jun 27;317(24):2515-2523.
Wang L, et al.
JAMA.
2017 Jun 27;317(24):2515-2523.
14.
Cernea S, Raz I.
Diabetes Care.
2011 May;34 Suppl 2(Suppl 2):S264-71.
Cernea S, Raz I.
Diabetes Care.
2011 May;34 Suppl 2(Suppl 2):S264-71.
